PYPing Yi

Ping Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ping Yi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Bert W. O’ Malley

    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA

    2 shared publications
  • Cristian Coarfa

    Affiliations Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America

    2 shared publications
  • Ramesh Singh

    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030

    2 shared publications
  • Subhamoy Dasgupta

    Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, USA

    2 shared publications
  • Amy E. Whitener

    Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77205, USA

    1 shared publication
  • Anil K. Panigrahi

    Affiliation Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant

    by Ross A. Hamilton, Basil Paul, Ping Yi, Kimal Rajapakshe, Anil K. Panigrahi, Sandra L. Grimm, Cristian Coarfa, Anna Malovannaya, Nancy L. Weigel, David M. Lonard, et al.

    ARv7, the most prevalent androgen receptor (AR) variant in castration-resistant prostate cancer, lacks the ligand binding domain (LBD), rendering it resistant to LBD-targeted therapies. Identifying new therapeutic targets requires defining the coregulators and associated regulatory enzymes that govern AR and ARv7 transcriptional activity. Here, we have developed a cell-free DNA pulldown assay employing androgen response elements (AREs) to isolate and characterize the AR- and ARv7-associated coregulator complexes formed on DNA. Mass spectrometry analyses of ARE DNA pulldowns revealed previously unrecognized AR and ARv7 associating coregulators, such as cullin-associated NEDD8-dissociated protein 1 (CAND1), in addition to previously known coregulators. ARv7 showed enhanced recruitment of a subset of AR associating coregulators. Knockdown of CAND1 in prostate cancer cells reduced the expression of AR and ARv7 target genes, supporting its role as a coactivator. Bioinformatic analyses of human prostate cancer clinical datasets revealed that CAND1 mRNA level correlated with disease status, with higher expression correlated with metastatic prostate cancer and poorer patient survival. We further show that DNA-dependent protein kinase (DNA-PK) phosphorylates both AR and ARv7, enhances their transcriptional activities, and stabilizes the interaction of CAND1 with AR- and ARv7- coregulator complexes. Collectively, these findings suggest that DNA-PK stimulates the AR and ARv7 activity through its enzymatic function and by stabilizing (or reinforcing) coactivator interactions, including those involving CAND1. In sum, this work advances our understanding of AR isoform actions and identifies additional potential therapeutic targets for castration-resistant prostate cancer.

  • Open Access

    Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications

    by Lance Edward V. Lumahan, Mazia Arif, Amy E. Whitener, Ping Yi

    Androgen receptor (AR) transcriptional activity significantly influences prostate cancer (PCa) progression. In addition to ligand stimulation, AR transcriptional activity is also influenced by a variety of post-translational modifications (PTMs). A number of oncogenes and tumor suppressors have been observed leveraging PTMs to influence AR activity. Subjectively targeting these post-translational modifiers based on their impact on PCa cell proliferation is a rapidly developing area of research. This review elucidates the modifiers, contextualizes the effects of these PTMs on AR activity, and connects these cellular interactions to the progression of PCa.


  • Open Access

    TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer

    by Ramesh Singh, Huan Meng, Tao Shen, Lance Edward V. Lumahan, Steven Nguyen, Hong Shen, Subhamoy Dasgupta, Li Qin, Dileep Karri, Bokai Zhu, et al.

    Castration-resistant prostate cancer (CRPC) poses a major clinical challenge with the androgen receptor (AR) remaining to be a critical oncogenic player. Several lines of evidence indicate that AR induces a distinct transcriptional program after androgen deprivation in CRPCs. However, the mechanism triggering AR binding to a distinct set of genomic loci in CRPC and how it promotes CRPC development remain unclear. We demonstrate here that atypical ubiquitination of AR mediated by an E3 ubiquitin ligase TRAF4 plays an important role in this process. TRAF4 is highly expressed in CRPCs and promotes CRPC development. It mediates K27-linked ubiquitination at the C-terminal tail of AR and increases its association with the pioneer factor FOXA1. Consequently, AR binds to a distinct set of genomic loci enriched with FOXA1- and HOXB13-binding motifs to drive different transcriptional programs including an olfactory transduction pathway. Through the surprising upregulation of olfactory receptor gene transcription, TRAF4 increases intracellular cAMP levels and boosts E2F transcription factor activity to promote cell proliferation under androgen deprivation conditions. Altogether, these findings reveal a posttranslational mechanism driving AR-regulated transcriptional reprogramming to provide survival advantages for prostate cancer cells under castration conditions.


  • Open Access

    The E3 ligase TRAF4 promotes IGF signaling by mediating atypical ubiquitination of IRS-1

    by Wenjuan Yu, Ramesh Singh, Zhao Wang, Bert W. O’mAlley, Ping Yi


  • Open Access

    TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis

    by Ramesh Singh, Dileep Karri, Hong Shen, Jiangyong Shao, Subhamoy Dasgupta, Shixia Huang, Dean P. Edwards, Michael M. Ittmann, Bert W. O’mAlley, Ping Yi

    Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of WT RTKs plays an important role in driving cancer progression. However, the mechanisms underlying how RTKs drive prostate cancer remain incompletely characterized. Here we show that non-proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK-mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer. We demonstrated here that it is a key player in regulating RTK-mediated prostate cancer metastasis. We further identified TrkA, a neurotrophin RTK, as a TRAF4-targeted ubiquitination substrate that promotes cancer cell invasion and found that inhibition of TrkA activity abolished TRAF4-dependent cell invasion. TRAF4 promoted K27- and K29-linked ubiquitination at the TrkA kinase domain and increased its kinase activity. Mutation of TRAF4-targeted ubiquitination sites abolished TrkA tyrosine autophosphorylation and its interaction with downstream proteins. TRAF4 knockdown also suppressed nerve growth factor (NGF) stimulated TrkA downstream p38 MAPK activation and invasion-associated gene expression. Furthermore, elevated TRAF4 levels significantly correlated with increased NGF-stimulated invasion–associated gene expression in prostate cancer patients, indicating that this signaling axis is significantly activated during oncogenesis. Our results revealed a posttranslational modification mechanism contributing to aberrant non-mutated RTK activation in cancer cells.